Cardiovascular Conditions and Erectile Dysfunction

Relationship Between Cardiovascular Conditions and Erectile Dysfunction

An association between sexual dysfunction, atherosclerosis, and hypertension has been established through epidemiological surveys, clinical trials, and cohort studies, according to the American College of Cardiology 1
Erectile dysfunction may be caused by hypertension-related vascular changes, but conversely, ED may also be part of the causal pathway to cardiovascular disease, as suggested by the American College of Cardiology 1, 2
ED can serve as an early marker of cardiovascular disease, potentially identifying men who require further cardiovascular evaluation, as reported in the Mayo Clinic Proceedings 3, 4

Traditional beta blockers can have negative effects on libido and erectile function, according to the American College of Cardiology 1, 2
Nebivolol, which has direct vasodilating properties, is less likely to cause ED than other beta blockers, as reported in the Mayo Clinic Proceedings and Hypertension 4, 5, 6
Beta blockers should not be abruptly discontinued preoperatively due to potential harm, as advised by the American College of Cardiology 1
Mineralocorticoid receptor antagonists (like spironolactone) can also negatively affect libido and erectile function, according to the American College of Cardiology 1
Angiotensin receptor blockers are less likely to cause ED than other antihypertensive agents like diuretics, as reported in the Mayo Clinic Proceedings 4, 5

PDE5 inhibitors (sildenafil, tadalafil, vardenafil) are effective first-line treatments for ED in patients with cardiovascular conditions, but they are contraindicated in patients taking nitrates due to risk of dangerous hypotension, as stated in the Praxis Medical Insights 7
PDE5 inhibitors can be safely coadministered with most antihypertensive medications and have additive effects on lowering blood pressure, according to the American College of Cardiology and Praxis Medical Insights 1, 7
Review current medications for potential contributors to ED and consider alternative treatments when possible, as recommended by the Praxis Medical Insights 7

Evaluate cardiovascular risk factors and categorize patient as low, intermediate, or high risk using validated risk assessment tools, as suggested by the Praxis Medical Insights 7
In high-risk patients, sexual activity should be deferred until the cardiac condition has been stabilized, as advised by the Mayo Clinic Proceedings 4, 5
Consider medication adjustments when appropriate, such as switching from traditional beta blockers to nebivolol, as reported in Hypertension 6
Sexual function should be incorporated into cardiovascular risk assessment for all men, as recommended by the Mayo Clinic Proceedings 4

The National Comprehensive Cancer Network recommends assessing cardiovascular risk before treating erectile dysfunction, as erectile dysfunction often serves as an early marker of silent cardiovascular disease, and determining if the patient can perform equivalent exercise to walking 1 mile in 20 minutes or climbing 2 flights of stairs in 20 seconds 8
High-risk patients should defer sexual activity until cardiac stabilization, according to the National Comprehensive Cancer Network 8
The National Comprehensive Cancer Network suggests addressing smoking cessation, weight loss, increased physical activity, and excess alcohol consumption to modify risk factors 8
Screening for psychosocial contributors including anxiety, depression, relationship issues, and substance use is recommended by the National Comprehensive Cancer Network 8
Reviewing all medications for erectile dysfunction-causing agents, such as opioids, hormone therapy, traditional beta-blockers, and spironolactone, is advised by the National Comprehensive Cancer Network 8

The American College of Physicians recommends initiating PDE5 inhibitors as first-line therapy for erectile dysfunction, with a conservative start and titration to maximum dose if needed, and at least 5 separate occasions at maximum dose before declaring treatment failure 8, 9
PDE5 inhibitors can be safely coadministered with most antihypertensive medications, according to the American College of Physicians 8
The National Comprehensive Cancer Network states that PDE5 inhibitors are absolutely contraindicated with nitrates or nicorandil due to dangerous hypotension risk 8

Intraurethral alprostadil suppositories, intracavernosal vasoactive drug injection therapy, and vacuum constriction devices are second-line options for erectile dysfunction treatment, as recommended by the National Comprehensive Cancer Network 8, 10
Penile prosthesis implantation is a third-line intervention for erectile dysfunction, according to the National Comprehensive Cancer Network 8

The American College of Physicians recommends that routine hormonal testing, such as testosterone and prolactin, is not recommended unless clinically indicated, as evidence is insufficient to determine net benefits 9, 10